publication date: Nov. 11, 2016

In Brief O’Dwyer Elected ECOG-ACRIN Group Co-Chair, Succeeds Comis 

PETER O’DWYER was elected group co-chair elect of the ECOG-ACRIN Cancer Research Group.

He will succeed Group Co-Chair Robert Comis, who is stepping down in 2019. 

O’Dwyer, a medical oncologist, is the chair of ECOG-ACRIN’s Gastrointestinal Cancer Committee and co-chair of the landmark phase II precision medicine trial known as NCI-MATCH (NCI Molecular Analysis for Therapy Choice).

He served as vice chair of ECOG-ACRIN from 1996 to 2013. His academic affiliations are director of the Developmental Therapeutics Program at the Abramson Cancer Center and professor of medicine at the University of Pennsylvania. O’Dwyer will serve with Mitchell Schnall, who will remain as the ECOG-ACRIN group co-chair representing the diagnostic imaging-based disciplines through the end of the next NCI funding cycle (2024).

Schnall is the Eugene P. Pendergrass Professor of Radiology and chair of the Radiology Department at the Perelman School of Medicine, University of Pennsylvania. After a transition period during which O’Dwyer will fully participate in strategic planning to set the Group’s future research directions, he will begin his tenure as group co-chair on March 1, 2019.O’Dwyer was elected Nov. 10 at the group meeting in Orlando.

ECOG-ACRIN comprises nearly 1,100 member institutions in the U.S. and around the world. Approximately 12,000 physicians, translational scientists, and associated research professionals from the member institutions are involved in group research, which is organized into three scientific programs: Cancer Control and Outcomes, … Continue reading O’Dwyer Elected ECOG-ACRIN Group Co-Chair, Succeeds Comis

To access this members-only content, please log in.
If you're not a subscriber why not join today?
If you believe you should be able to view this area but cannot log in, then please contact us and we will try to rectify this issue as soon as possible.
To gain access to the members only content click here to subscribe.
You will be given immediate access to premium content on the site.
Click here to join.

Copyright (c) 2017 The Cancer Letter Inc.